Today: 11 June 2026
Lockheed Martin stock jumps nearly 3% to start 2026 — contracts, rates and earnings in focus

Lockheed Martin stock jumps nearly 3% to start 2026 — contracts, rates and earnings in focus

NEW YORK, January 3, 2026, 05:58 ET — Market closed

  • Lockheed Martin shares last closed up about 2.8% at $497.07.
  • Defense peers also rose in the first U.S. trading session of 2026.
  • Next catalysts include key U.S. data and a late-January earnings window.

Lockheed Martin Corp stock rose 2.8% at its last close, ending at $497.07 as U.S. markets wrapped the first trading day of 2026.

The move matters now because investors are re-positioning for January with defense spending and contract flow back in focus, even as the broader market takes its cues from interest rates.

For Lockheed, the world’s largest defense contractor, the stock often tracks both the drumbeat of Pentagon awards and the bigger question of where bond yields are headed.

On Friday, Lockheed outpaced the broader market and most large defense peers, while the S&P 500 and Dow also finished higher, market data showed. Trading volume was modest versus recent averages, and the stock remained below its October high.

Company-specific attention has centered on a Pentagon award disclosed on Dec. 31: the Defense Department said Lockheed received a $328.5 million contract tied to a foreign military sale to Taiwan for Legion infrared search-and-track sensor pods, with work in Orlando, Florida, expected to run through June 2031.

Foreign military sales, or FMS, are government-to-government transactions in which the U.S. acts as the intermediary buyer and seller for defense equipment.

Macro cross-currents are also in play. Investors are watching next week’s U.S. jobs report due Jan. 9 and inflation data on Jan. 13 for signals on the Federal Reserve’s rate path, after a holiday-thinned stretch of trading. “The market is looking for direction,” said Matthew Maley, chief market strategist at Miller Tabak. Reuters

That backdrop can matter for Lockheed because big defense stocks often trade like steady-cash-flow industrials, making them sensitive to shifts in rate expectations and the valuation multiples investors are willing to pay.

Before the next session begins on Monday, traders will be looking for any fresh defense contracting headlines or geopolitical developments that can move the group, particularly around U.S. security partnerships in the Indo-Pacific.

The next major company waypoint is earnings. Nasdaq’s market calendar points to an estimated report date around Jan. 27, though the date can change once the company formally announces its schedule.

From a chart perspective, traders will be watching the $500 level as a near-term pivot, after Friday’s session saw shares trade roughly between $476 and $497, according to historical price data.

Stock Market Today

  • Live Cattle Futures Edge Higher Amid Mixed USDA Beef Prices
    June 11, 2026, 10:54 AM EDT. Live cattle futures rose by $1.45 to $1.60 across most front months on Wednesday, with December delivery slightly down. Feeder cattle futures gained $2.40 to $2.90 by midday. Open interest increased by 1,293 contracts. Managed money trimmed net long positions in live cattle futures and options by 7,083 contracts, totaling 101,265, while feeder cattle spec funds reduced holdings by 470 contracts. USDA reported a decline in wholesale boxed beef prices, with Choice boxes down $1.68 to $359.36 and Select down $3.15 to $344.88. Federally inspected cattle slaughter rose to an estimated 123,000 head Wednesday, exceeding last week but falling short of last year. The mixed data signals ongoing volatility in cattle markets as traders assess supply and demand factors.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Carvana stock drops 5% after insider sale filings; what CVNA investors watch next week
Previous Story

Carvana stock drops 5% after insider sale filings; what CVNA investors watch next week

Markets brace for Monday after U.S. strike on Venezuela: oil, stocks and safe-haven demand in focus
Next Story

Markets brace for Monday after U.S. strike on Venezuela: oil, stocks and safe-haven demand in focus

Go toTop